2nd Due Diligence Summit for Life Sciences
Date: | 09-Jun-15 to 10-Jun-15 |
Location: | Hilton Boston Logan Airport / Boston / United States |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
Mergers, acquisitions, in-licensing and out-licensing have dramatically increased in popularity as a revenue stream for life science organizations. This is due to both the length of time it can take to research a new product from the ground up, and the progressively crowded marketplace. The life sciences industry has experienced success through increased licensing, which has moved it from a secondary activity to a necessary measure to ensure a healthy bottom line.
Big pharma, innovative biotechs and medical device companies have millions of dollars riding on the success of licensing deals. A deal gone wrong can mean massive debts and wasted resources on all sides. It’s crucial to be able to find a licensing partner you can trust, and to be able to search out and identify potential partnerships and valuable products.
ExL Events’ 2nd Due Diligence Summit for Life Sciences, convening in Boston on June 9-10, 2015, was designed after conducting extensive research with your peers and learning about challenges you face and the thought leaders who can help you solve them. This is an educational event focused on how to run a tight ship throughout the due diligence process by presenting you with experienced speaking faculty members from Pfizer, AstraZeneca, Boehringer Ingelheim, and more!
Big pharma, innovative biotechs and medical device companies have millions of dollars riding on the success of licensing deals. A deal gone wrong can mean massive debts and wasted resources on all sides. It’s crucial to be able to find a licensing partner you can trust, and to be able to search out and identify potential partnerships and valuable products.
ExL Events’ 2nd Due Diligence Summit for Life Sciences, convening in Boston on June 9-10, 2015, was designed after conducting extensive research with your peers and learning about challenges you face and the thought leaders who can help you solve them. This is an educational event focused on how to run a tight ship throughout the due diligence process by presenting you with experienced speaking faculty members from Pfizer, AstraZeneca, Boehringer Ingelheim, and more!
Exhibitors
Brian Axe, Due Diligence Leader, ELANCO Robert Bagdorf, M.D., MBA Vice President, Biopharmaceuticals Search and Evaluation Worldwide Business Development, PFIZER INC. David Berger General Counsel, WEST-WARD Alex Chang Director, Global Licensing and Business Development, GLENMARK Philip Datlow Director and Senior IP Counsel, BOEHRINGER INGELHEIM Carl Jessop Due Diligence Director, ASTRAZENECA Gavin T. Malenfant Vice President, Head of Operations, GENZYME, A SANOFI COMPANY Adam Muzikant Executive Director, Business Development, AMAG PHARMACEUTICALS Mike Myers Senior Director, LRL, Due Diligence, ELI LILLY
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today